Liminatus Pharma, Inc.
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
LIMN | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 6 CENTERPOINTE DR., 90623 LA PALMA
- Website:
- http://liminatuspharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies designed to modulate the body's immune system. The company's lead program is focused on a proprietary therapeutic that blocks the CD47 checkpoint, a mechanism cancer cells use to evade the immune system. By targeting CD47, its treatments aim to enable the immune system to recognize and eliminate tumors. The company's pipeline includes candidates developed through licensing agreements with research institutions. Liminatus Pharma became a publicly traded company following a business combination with a special purpose acquisition company (SPAC).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Liminatus Pharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Liminatus Pharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Liminatus Pharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
